Crossmark

Pegylated interferon-based sequential therapy for treatment of HBeAg reactive pediatric chronic hepatitis B—First study in children

Crossref DOI link: https://doi.org/10.1007/s12664-018-0878-1

Published Online: 2018-08-31

Published Print: 2018-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lal, Bikrant Bihari

Sood, Vikrant

Khanna, Rajeev

Rawat, Dinesh

Verma, Sanjeev

Alam, Seema
License Information

Text and Data Mining valid from 2018-07-01
More Information

Article History

Received: 7 April 2018

Accepted: 2 August 2018

First Online: 31 August 2018

Compliance with ethical standards

:

: BBL, VS, RK, DR, SV, and SA declare that they have no conflict of interest.

: All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards. Approval for the study was obtained from Institutional Review Board (IEC/IRB No: 36/M-2)

: Informed consent was obtained from parents of all children included in the study.

: The authors are solely responsible for the findings and the content of the paper. In no way, the Honorary Editor-in-Chief, Editorial Board Members, and the printer/publishers are responsible for the results/findings and the content of this article.